• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Suono Bio rasies $8.5M in oversubscribed Series A

July 13, 2021 By Sean Whooley

Suono BioSuono Bio announced today that it raised $8.5 million for its drug delivery platform in an oversubscribed Series A financing round.

Foxborough, Mass.-based Suono Bio had its financing led by Axil Capital and Mizuho Securities Principal Investment. Taiwanaia Capital and other investors also participated.

According to a news release, Suono Bio will use the funds raised to advance its lead programs in inflammatory bowel disease and to expand its pipeline.

Suono Bio’s platform design enables the rapid, targeted delivery of drugs, including gene therapies, the company said. It developed the platform for therapeutics for inflammatory-mediated diseases in professor Robert Langer’s laboratory at the Massachusetts Institute of Technology with the aim of enabling, rapid, localized delivery of small molecules, biologics and nucleic acids and gene therapies without the need for encapsulation of the therapeutic.

“We are thrilled to have marquee investors involved with Suono Bio and speaks to the rapid pace with which the team has taken a conceptual technology from Prof. Langer’s lab and operationalized it to address pressing health issues,” Suono Bio CEO Scott Kellogg said in the release. Proceeds from the Series A financing will allow completion of the development of the company’s first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: suonobio

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS